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Monoclonal antibodies are being used experimentally in the diagnosis and 
treatment of cancer and other diseases. School of Medicine researcher 
Jacqueline Sharon, Ph.D., is working to improve the design of these 
"magic bullets." See story on page 3. 
Form of vitamin D 
may offer hope for 
psoriasis sufferers 
A Boston University School of Med-
icine researcher is experimenting with 
a form of vitamin D not presently avail-
able to consumers as a possible safe 
and effective therapy for the stubborn 
clinical problem of psoriasis, and is 
achieving results that bode well for the 
more than 50 million people around 
the world who suffer from the skin dis-
ease. 
A disorder of unknown cause, 
psoriasis afflicts some 1 to 3 percent 
of the total world population and is 
characterized by excessive production 
of epidermal cells, producing patches 
of thick scales that are itchy, burning, 
prone to bleeding and unsightly. Cur-
rently, there is no totally effective treat-
ment or cure for the disease, and the 
therapies that do exist, such as ex-
posure to ultraviolet light or steroid 
medications, often are ineffective after 
long-term use or possibly even toxic. 
Michael F. Holick, Ph.D., M.D., a 
professor of medicine and director of 
the newly established Vitamin D, Skin 
and Bone Research Laboratory and 
director of the General Clinical 
Research Center at BUSM, is ex-
perimenting with the active form of 
vitamin D as a possible safe and effec-
tive therapy for psoriasis. Vitamin D, 
which is obtained from the diet or as a 
result of exposure of the skin to sun-
light, is activated in the liver and kid-
ney to form 1,25-dihydroxyvitamin D3. 
As an endocrinologist who 
continued on page 5 
Michael F. Holick, Ph.D., M.D., is experimenting with a promising new therapy for the 
stubborn clinical problem of psoriasis. (Photo by Gustav Freedman) 
BUSM researchers test new treatment 
to reduce pneumonia in hospital patients 
One of the most serious problems con-
fronting hospitals is nosocomial, or 
hospital-acquired, infections in 
patients. 
On average, 5 to 10 percent of 
hospitalized patients develop such in-
fections, said Donald E. Craven, M.D., 
an associate professor of medicine at 
Boston University School of Medicine. 
Of these hospital-acquired infections, 
pneumonia is the most serious. 
"Nosocomial pneumonia, which ac-
counts for about 15 percent of all 
nosocomial infections, is the second 
most common hospital-acquired infec-
tion in the United States," said 
Craven. 
Although less common than urinary 
tract infections, nosocomial pneu-
monia is associated with higher mor-
bidity and mortality rates, said the in-
fectious disease specialist. Mortality 
rates are greater than 50 percent for 
patients who develop pneumonia in 
the medical or surgical intensive care 
unit. Moreover, he noted, the develop-
ment of pneumonia in the hospital 
adds another unnecessary burden to 
a patient who is seriously ill. 
Most efforts aimed at reducing the toll 
exacted by nosocomial pneumonia 
have centered on the use of new an-
tibiotics, said Craven. "The perception 
continued on page 2 
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has been that there's very little we can 
do to prevent nosocomial pneumonia, 
so the emphasis has been on trying to 
develop new types of antibiotics to 
treat it," he said. 
According to Craven, a wide range 
of factors has been blamed for the 
high rate of pneumonia among hospi-
talized patients. Patients who are 
very ill, for example, have weakened 
immune systems. And despite advan-
ces in techniques for minimizing infec-
tions, hospitals still have difficulty 
preventing the spread of infectious 
agents. 
Now, however. Craven and his as-
sociates have identified a new 
strategy for preventing pneumonia in 
intensive care unit patients who need 
mechanical ventilators in order to 
breathe. In a recent report published 
in the New England Journal of 
Medicine, the group said that maintain-
ing the patient's normal stomach acid 
may hold the key to reducing the in-
cidence of pneumonia. 
Craven's specific concern is the 
medication routinely used to prevent 
gastrointestinal bleeding among 
patients in intensive care units. "Vir-
tually all patients who enter an inten-
sive care unit get regular antacids that 
neutralize gastric acid, or therapy with 
histamine type 2 (H2) blockers, which 
block gastric acid secretion," he said. 
"The purpose of the therapy is to 
reduce the risk of gastrointestinal 
hemorrhage, which is a serious 
problem in patients who are critically 
ill." 
In reducing levels of gastric acid, 
however, there is overgrowth of bac-
teria in the stomach. These may 
reflux into the throat and be aspirated 
into the lung, resulting in the 
pneumonia. 
"Four years ago," said Craven, 
"our group did a study here at Boston 
City Hospital in which we analyzed the 
risk factors for nosocomial pneumonia 
among intensive care patients who 
needed mechanical respirators to 
breathe. One of the risk factors most 
strongly associated with pneumonia 
was drugs that block or neutralize 
gastric acids." 
According to Craven, this initial 
study has had little impact on hospital 
treatment of intensive care patients be-
cause, until recently, there has been 
no alternative therapy to antacids or 
H2 blockers. Since that study, 
however, sucralfate, a new form of 
medication for preventing such bleed-
ing, has been developed. Sucralfate 
works by creating a protective coating 
in the stomach rather than by reduc-
ing gastric acid levels. It was the 
development of such an agent that 
prompted Craven and Michael Driks, 
M.D., an infectious disease fellow, to 
perform the study, which recently was 
published. 
"We wanted to see whether we 
could reduce the incidence of 
pneumonia by using sucralfate in-
stead of the usual regimen of antacids 
or H2 blockers," said Craven. "We 
felt that maintaining relatively high 
levels of gastric acid would decrease 
the growth of pneumonia-causing bac-
teria in the stomach, and the result 
would be fewer cases of pneumonia." 
The patients selected for the study 
were critically ill, intensive care unit 
patients who required the aid of 
mechanical ventilators. The types of 
problems that had brought the 
patients to the hospital included heart 
attacks, head trauma, drug overdoses 
and severe respiratory disease. 
Of the 130 patients enrolled in the 
study, roughly half were randomly 
chosen to receive conventional treat-
ment with H2 blockers or antacids or 
both, while the rest received sucral-
fate. 
The specific type of bacteria the re-
searchers were interested in are 
called gram-negative bacilli. These 
rod-shaped organisms have been pin-
pointed as the major culprits causing 
hospital-acquired pneumonia. 
Donald E. Craven, M.D., shown with a 
patient, and his colleagues are studying 
the effects of a new drug for reducing the 
incidence of hospital-aquired pneumonia 
in critically ill patients. (Photo by 
Bradford F. Herzog) 
"We looked at the rates at which 
these bacilli were present in both the 
stomach and the pharynx of the two 
treatment groups," said Craven, "and 
we found that the levels of pneumonia-
causing bacteria were often several or-
ders of magnitude higher in patients 
receiving H2 blockers or antacids com-
pared to patients given sucralfate." 
The investigators found that the 
rate of pneumonia in the antacid/H2 
group was nearly double that of the 
sucralfate group (23 percent as com-
pared to 12 percent). 
Craven said the data suggest "that 
sucralfate appears to be as effective 
as H2 blockers and antacids at 
preventing stress bleeding, but is as-
sociated with a much lower rate of 
nosocomial pneumonia." He predicted 
that his group's study, when combined 
with similar findings from other medi-
cal centers, is likely to have a major 
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Building better monoclonal antibodies 
subject of BUSM researcher's efforts 
impact on the management of stress 
bleeding in intensive care patients. 
In addition to Driks, other as-
sociates at Boston City Hospital who 
have been instrumental in the 
project's success include: 
Bartolome R. Celli, M.D., an assistant 
professor of medicine at BUSM and a 
pulmonary specialist; Harrison W. 
Farber, M.D., an assistant professor 
of medicine; Marie Manning, a medi-
cal technician; William R. McCabe, 
M.D., a professor of medicine; and 
Suzanne A. Wedel, M.D., an assistant 
professor of surgery. 
—Richard P. Anthony 
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Monoclonal antibodies represent one 
of the most exciting areas of basic re-
search under investigation today. As 
specially designed "magic bullets" 
that can seek out and bind to specific 
targets with great efficiency, they are 
being experimented with in both the 
diagnosis and treatment of various dis-
eases, particularly cancers. Yet, be-
cause no one fully understands the 
molecular interactions between 
natural antibodies and their target an-
tigens, there is room for improvement 
in the design of new monoclonal 
antibodies. 
Since joining Boston University 
School of Medicine in 1985, 
Jacqueline Sharon, Ph.D., an assis-
tant professor of pathology and 
biochemistry, has been working on 
In developing more efficient monoclonal 
antibodies, Sharon first must grow them in 
bacterial plasmids. Here, Sharon transfers 
bacteria containing antibody genes. 
(Photo by Gustav Freedman) 
the problem of how to build a better 
monoclonal antibody. The clinical ap-
plications of her work someday may in-
clude the eradication of tumors and 
the control of the rejection of 
transplanted organs. 
Normally, we defend ourselves 
against disease with the help of 
antibodies, specialized proteins 
produced as needed by certain cells 
in the body to neutralize foreign sub-
stances, or antigens. Even under nor-
mal conditions, however, not all types 
of antibodies attack and bind to target 
antigens with 100-percent efficiency. 
There may be factors in an antibody's 
gene structure that make it less effi-
cient than it could be. 
One reason for developing 
monoclonal antibodies is to overcome 
the binding deficiency of natural 
antibodies and produce, in the 
laboratory, a pure strain of highly 
specific antibody that will react strong-
ly with a particular antigen. However, 
because monoclonal antibodies today 
are made by first raising the antibody 
of choice in a mouse and then fusing 
it with a tumor cell line to produce a 
clone of that antibody, there may be a 
problem with rejection when the new 
antibody is introduced into another 
species, such as a human, to do its 
work. 
"Most experimental antibodies are 
from mouse systems rather than from 
humans for ethical reasons and be-
cause human cell lines cultured for 
antibodies lose their productivity and 
die out after a while," explained 
Sharon. 
In order to design the most effec-
tive antibody and to overcome the ten-
dency for rejection, Sharon is inves-
tigating which areas of an antibody 
molecule are crucial to its operation 
and which are not. In her experiments, 
she introduces mutations into a gene 
responsible for producing an antibody 
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Jacqueline Sharon, 
Ph.D., is investigating 
what areas of an 
antibody molecule 
are crucial to its 
operation. (Photo by 
Gustav Freedman) 
and observes how those changes af-
fect the antibody's structure and, 
therefore, its ability to bind to the tar-
get antigen. 
She uses a technique called 
oligonucleotide-directed mutagenesis 
that allows her to direct whatever 
changes she wants by making specific 
alterations in the chemical composi-
tion of the gene. Sharon then 
measures the binding constant—the 
strength of the interaction between the 
antibody and the antigen. Her goal is 
to find out if there are certain positions 
in the antibody gene sequence that 
are especially important to the binding 
constant. If so, it may be possible to 
manufacture an antibody with an op-
timum binding ability for a particular 
antigen. 
In her current studies, which are 
funded by the National Institutes of 
Health and the Whitaker Foundation, 
Sharon is looking at two types of 
antibodies that bind to the same an-
tigen, one of which has a binding ef-
ficiency 200 times greater than the 
other. A comparison of the 
antibodies' amino acid sequences has 
revealed eight differences in one 
area—called the heavy chain portion— 
of the molecules. What Sharon wants 
to know is how many of these differen-
ces contribute to the stronger interac-
tion. 
"By using oligonucleotide-directed 
mutagenesis, you can ask how many 
of these differences actually con-
tribute to turning the sequence of 
antibody X into antibody Y, and you 
can study them one by one. You can 
ask at each stage what is the effect of 
changing this particular amino acid," 
said Sharon. 
According to Sharon, every 
antibody molecule has a variable 
region that actually does the work of 
binding to an antigen and a constant 
region that is not directly involved. 
Within the variable region, there are 
even smaller regions known as hyper-
variable regions that may be respon-
sible for the optimal binding efficiency. 
In one set of experiments involving 
a mouse-model system, Sharon plans 
to determine an antibody's optimal 
protein sequence for binding efficien-
cy and then to graft the small hyper-
variable portion of that molecule into 
its framework and then into the con-
stant region of another mouse 
antibody molecule to see if specificity 
to the target antigen is retained. 
Theoretically, this would work in 
humans, too. 
"The idea is that if you take just the 
variable region of a mouse antibody 
and-hook it to a human constant 
region, you won't get an immune 
response against the constant region 
when you put the whole molecule into 
a human for treatment," she ex-
plained. "And if you could put an 
even smaller part, the hypervariable 
regions, into a human constant region, 
you have an even better chance that 
there won't be an immune response." 
In addition, Sharon is cloning DNA 
from a rat's variable region and fusing 
it onto a mouse antibody constant 
region to test the rejection response. 
Most of the work involved in research 
of this sort, she said, is in trying to get 
the antibody genes to clone in the first 
place. Sharon expects this fine-tuning 
to take the better part of a year before 
she has the newly designed 
monoclonal antibodies to test in the 
animal systems. 
—Caroline H. Lupfer 
Suggested Further Readings 
1. Sharon, J. etal: Expression of 
a VHCK chimaeric protein in mouse 
myeloma cells. Nature 309: 364-367, 1984. 
2. Sharon, J. etal: Site directed 
mutagenesis of an invariant amino acid 
residue at the V-D junction of an antibody. 
Proa Natl Acad Sci. USA 83:2628-2631, 
1986. 
5 Research in Progress/Spring/1988 
Photo at left shows a patient with psoriasis before the vitamin D treatment, and photo at 
right shows the same patient following the treatment. (Photos courtesy of 
Michael Holick, Ph.D., M.D.) 
Psoriasis... 
continued from page 1 
specializes in bone metabolism, 
Holick is well aware of the multi-
faceted role vitamin D plays in the ab-
sorption and regulation of calcium in 
the body and the maintenance of heal-
thy bone. In addition, Holick and his 
colleagues have been looking at the 
role the active form of the vitamin may 
have in the treatment of previously in-
transigent skin diseases. 
The principal natural source of 
vitamin D lies not in food but in the ex-
posure of skin to sunlight. High-ener-
gy, ultraviolet sunlight enters the skin 
and is absorbed by provitamin D3, a 
precursor of cholesterol. A natural 
photochemical chain reaction converts 
these molecules to provitamin D3, 
which in turn is converted through a 
thermal reaction in the epidermis to 
the more stable molecule, vitamin D3. 
Vitamin D3 enters and is carried by 
the circulation to the liver and kidney, 
where it is metabolized to the active, 
hormonal form—1, 25-dihydroxy-
vitamin D3. 
Holick, who also heads the 
Osteoporosis Clinic of the Evans Medi-
cal Group at the University Hospital 
and is chief of the Endocrine Unit at 
Boston City Hospital, was one of the 
discoverers of this active form of 
vitamin D 16 years ago, and also was 
the first to chemically synthesize it in 
the laboratory for clinical use. 
While it has been long understood 
that the skin produces vitamin D, 
Holick's group found that the skin also 
responds to the active form of the 
vitamin and does so in a very specific 
manner. 
The active form of the vitamin, ab-
breviated as 1,25-(OH)2-D3, is a 
potent hormone for inhibiting prolifera-
tion and inducing terminal differentia-
tion of human epidermal cells, ex-
plained Holick. Many tissues of the 
body, including the skin, have recep-
tors for 1,25-(OH)2-D3. Given that 
psoriasis is a disease characterized 
by hyperproliferation of epidermal 
cells, Holick reasoned that if the recep-
tors were there, then the hormonal 
form of the vitamin should act to 
prevent further proliferation and in-
duce differentiation into normal skin 
cell types. 
In a recent trial conducted in the fall 
and winter in Boston to see how 1,25-
(OH)2-D3, administered either topical-
ly or orally, would work against 
psoriasis, Holick found excellent and 
rapid clearing of the skin in about 30 
to 40 percent of the individuals 
studied. In another 30 to 40 percent 
there was a good, but not total, 
response, which continued to improve 
slowly over time. In some patients, 
however, neither application seemed 
to work. In these cases, the question 
became: What is it that keeps these 
individuals from having a good 
response? Cultured tissue samples 
from resistant patients showed that 
there were receptor sites for the active 
form similar in quantity and quality to 
those found in normal skin. 
In his studies, Holick tested the ef-
fects of 1,25-(OH)2-D3 on cultured 
fibroblasts (cells from the dermis) and 
keratinocytes (cells from the epider-
mis) from psoriatic patients and found 
that the active form of the vitamin 
caused a dose-dependent inhibition of 
proliferation and induction of terminal 
differentiation similar to its effect on 
keratinocytes of normal skin. He then 
treated 17 patients with psoriasis vul-
garis with orally or topically ad-
ministered 1,25-(OH)2-D3. 
In 10 of 14 patients who were 
treated orally, there was a significant 
clearing of the psoriatic plaques. 
Three patients had complete clearing 
while they were on the drug, whereas 
only four of the 17 received little or no 
benefit from the therapy. Of the three 
patients who received topically ad-
ministered 1,25-(OH)2-D3, all showed 
a rapid response with complete clear-
ing after six weeks of therapy. 
The responsiveness of patients to 
the active form of vitamin D seemed 
to correlate with the in vitro response 
of the patients' cultured skin samples 
to the antiproliferative activity of the 
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drug. In some of the patients treated 
orally, however, there were some 
reappearances one or two months 
after the therapy was discontinued. 
These lesions generally were smaller 
and were located in areas previously 
uninvolved, but also were slower to 
respond to a reapplication of the 1,25-
(OH)2-D3. 
One potential drawback in using 
1,25-(OH)2-D3 is the possibility of hy-
percalciuria or hypercalcemia, an ex-
cess of calcium in the urine or blood, 
which could lead to kidney stones or 
kidney damage. This aspect was 
monitored carefully in Holick's study 
by measurements of concentrations of 
calcium in the blood and urine every 
two weeks. Measurements taken 
prior to therapy indicated that 
psoriasis is not caused by a deficiency 
of the active form of vitamin D. Fur-
thermore, it was discovered that the 
patients could tolerate a single large 
dose (2.0 micrograms/day) at bedtime 
much better and with no toxicity than 
smaller doses during the day. 
Based on these preliminary find-
ings, Holick believes that orally or topi-
cally administered 1,25-(OH)2-D3 may 
be a safe and effective alternate 
therapy for the treatment of psoriasis. 
In addition, an evaluation of the 
responsiveness of cultured fibroblasts 
and keratinocytes from psoriatic 
patients to the antiproliferative activity 
of 1,25-dihydroxyvitamin D3 may be a 
useful predictor of which patients will 
respond to this approach. 
Since he began his studies using 
the active form of vitamin D, Holick 
has received letters from approximate-
ly 3,000 people eager to participate in 
further trials of the drug, which now 
are being carried out in BUSM's 
General Clinical Research Center. 
"We think that the active form of 
vitamin D may be an important 
therapy alone, in combination with 
other treatments, or in the main-
tenance of remission for psoriatic 
patients," said Holick. Further trials 
are under way to test these 
hypotheses, and in vitro studies are in 
progress to determine the biological 
significance of the partial resistance to 
1,25-(OH)2-D3. 
—Caroline H. Lupfer 
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